Faron Pharmaceuticals Oy Past Earnings Performance
Past criteria checks 0/6
Faron Pharmaceuticals Oy's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 105.5% per year.
Key information
-20.1%
Earnings growth rate
-7.4%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | -105.5% |
Return on equity | -2,292.2% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Faron Pharmaceuticals Oy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -32 | 9 | 18 |
31 Mar 24 | 0 | -31 | 9 | 19 |
31 Dec 23 | 0 | -31 | 9 | 20 |
30 Sep 23 | 0 | -30 | 9 | 19 |
30 Jun 23 | 0 | -29 | 8 | 19 |
31 Mar 23 | 0 | -29 | 8 | 20 |
31 Dec 22 | 0 | -29 | 8 | 21 |
30 Sep 22 | 0 | -26 | 9 | 20 |
30 Jun 22 | 0 | -24 | 11 | 18 |
31 Mar 22 | 0 | -22 | 10 | 18 |
31 Dec 21 | 0 | -21 | 10 | 17 |
30 Sep 21 | 0 | -21 | 8 | 17 |
30 Jun 21 | 0 | -20 | 5 | 17 |
31 Mar 21 | 0 | -19 | 5 | 16 |
31 Dec 20 | 0 | -17 | 5 | 14 |
30 Sep 20 | 0 | -16 | 4 | 12 |
30 Jun 20 | 0 | -14 | 4 | 11 |
31 Mar 20 | 0 | -14 | 4 | 11 |
31 Dec 19 | 0 | -13 | 3 | 10 |
30 Sep 19 | 0 | -13 | 3 | 10 |
30 Jun 19 | 0 | -12 | 3 | 10 |
31 Mar 19 | 0 | -16 | 3 | 13 |
31 Dec 18 | 0 | -20 | 4 | 16 |
30 Sep 18 | 1 | -24 | 4 | 21 |
30 Jun 18 | 1 | -28 | 4 | 25 |
31 Mar 18 | 1 | -25 | 3 | 22 |
31 Dec 17 | 1 | -21 | 3 | 19 |
30 Sep 17 | 2 | -17 | 3 | 15 |
30 Jun 17 | 2 | -14 | 3 | 11 |
31 Mar 17 | 2 | -12 | 3 | 10 |
31 Dec 16 | 2 | -10 | 2 | 9 |
30 Sep 16 | 0 | -9 | 3 | 8 |
30 Jun 16 | 0 | -7 | 3 | 6 |
31 Mar 16 | 1 | -7 | 3 | 5 |
31 Dec 15 | 1 | -6 | 3 | 4 |
30 Sep 15 | 1 | -5 | 2 | 3 |
30 Jun 15 | 1 | -3 | 1 | 2 |
31 Mar 15 | 1 | -2 | 1 | 2 |
31 Dec 14 | 1 | -1 | 0 | 1 |
31 Dec 13 | 0 | -2 | 0 | 2 |
Quality Earnings: FARN is currently unprofitable.
Growing Profit Margin: FARN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FARN is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare FARN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FARN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: FARN has a negative Return on Equity (-2292.17%), as it is currently unprofitable.